What is INQOVI?


MDS can require lifelong treatment1*
Receiving treatment for MDS, including CMML, can be challenging for some patients and caregivers, requiring2-4

Additional travel to and from chemotherapy infusion centers or hospitals for IV infusions or subcutaneous injection
- Visits may be long and frequent, for multiple cycles (5-7 days/cycle)3,5

Venous access and parenteral administration4,6
*Especially in the case of transplant-ineligible patients. IV=intravenous


Cedazuridine enables oral delivery of decitabine7
INQOVI® (decitabine and cedazuridine) tablets are 1 pill, taken once daily for 5 days out of a 28-day cycle. See full dosing information here. INQOVI is a fixed-dose combination of decitabine (35 mg) and cedazuridine (100 mg), a cytidine deaminase (CDA) inhibitor that enhances oral bioavailability of decitabine and also increases its systemic exposure.


- Decitabine is a nucleoside metabolic inhibitor that is believed to exert its effects by causing DNA hypomethylation. This may restore normal function to genes that are critical for the control of cellular differentiation and proliferation
- Nonproliferating cells are relatively insensitive to decitabine
- CDA is an enzyme responsible for degradation of nucleosides such as decitabine into inactive metabolites, thus limiting their oral bioavailability
- Administration of cedazuridine with decitabine increases systemic exposure of decitabine
DNMT=DNA methyltransferase.
Your patients may be appropriate for INQOVI, if they are7:
- Diagnosed with de novo or secondary MDS, including CMML
- Classified as intermediate- or high-risk MDS
- Have not received prior treatment or have previously been treated
ADDITIONAL PATIENT CONSIDERATIONS:
- Wish to take their HMA therapy in the comfort of their own home
- Unable to have, or do not wish to have, infusion port placement
- Do not have regular support to manage travel to the infusion center
Download these helpful INQOVI resources:
Brochure
Brochure
Brochure
Brochure